Vantage Consulting Group’s NeoGenomics NEO Stock Holding History

Vantage Consulting Group’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-327	Closed	-$18K	–	1038
2020 Q4	$18K	Buy	+327	New	+$14.8K	﹤0.01%	926

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

KFO

Kopp Family Office Bloomington, Minnesota $163M AUM 22.57% 1-Year Est. Return

Vantage Consulting Group's NEO Position: Q1 2021 in Review

Vantage Consulting Group sold out of NeoGenomics (NEO) in Q1 2021, closing a stake of 327 shares — an estimated $18K sold.

Vantage Consulting Group first reported a position in NEO in Q4 2020 and held it in 1 quarter. The position peaked at $18K in Q4 2020. 332 funds tracked by Wall St. Rank hold NEO as of Q1 2021.

Vantage Consulting Group reported no remaining NeoGenomics position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 327 NeoGenomics shares in Q1 2021, an estimated $18K.
Vantage Consulting Group first reported a position in NeoGenomics in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's NeoGenomics position peaked at $18K in Q4 2020.
332 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.